News in Brief
AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2023 MidWinter Meeting in Orlando (FL) on February 11-15 2023
Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results about the effect of AC102 in a model of electrode insertion trauma at the ARO 2023 in Orlando. Moreover, Dr Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will talk about the results of a Phase I clinical trial with AC102 in healthy volunteers.
Inner Ear Therapeutics Summit 2022: AudioCure Pharma GmbH will present latest data on lead product AC102
At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022.
AudioCure Pharma’s AC102 receives FDA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)
The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...
World Hearing Day 21: WHO reports alarming figures on hearing loss – AudioCure determined to provide effective treatments as part of the solution
The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people will be living with some degree of hearing loss unless action is taken. In other words: In less than 30 years 1 in 4 people worldwide could be affected.
AudioCure Pharma enters clinical development phase with lead molecule AC102
AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102. Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear.
The AudioCure Family Grows Further
AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...
AudioCure Pharma’s AC102 receives EMA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)
The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural...
The AudioCure Family is Growing
We are very happy to announce that we have expanded our team with further experts for formal preclinical and clinical development to propel our way into the clinical stage …
AudioCure appoints Dr. Reimar Schlingensiepen as CEO
Reimar Schlingensiepen succeeds Prof. Hans Rommelspacher, the founder of AudioCure, as CEO. Prof. Rommelspacher will continue as CSO.
Relaunch of the AudioCure Website
It is with great pleasure that we announce the relaunch of our corporate brand and website. The brand design has been refined and updated to reflect AudioCure’s innovative and forward-thinking outlook. Meanwhile, we hope that with its clear structure, easy navigation...